Belgian pharma group UCB acquires Candid Therapeutics

Belgian pharmaceutical group UCB announces the acquisition of Candid Therapeutics for an undisclosed amount.

Published 12sem1 sourceNotable

≈ 17sSpeed

The fact

This operation strengthens the laboratory's presence in immunotherapy and innovative treatments.

Integration is expected to begin before the end of 2026.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on May 4, 2026